Antares Pharma

Antares’ VIBEX MTX trial meets primary endpoints

Friday, August 5, 2011

Antares Pharma has reported positive results of a clinical study evaluating VIBEX MTX, a proprietary auto injector product designed to give a rapid subcutaneous injection of methotrexate (MTX) for the treatment of rheumatoid arthritis (RA). The clinical pharmacokinetic study evaluated several dose strengths of MTX delivered by a healthcare professional to RA patients with VIBEX MTX versus subcutaneous or intramuscular injection using a conventional needle and syringe. The primary end points were met with all three methods of administration providing equivalent performance in the patients studied, together with comparable safety.

[Read More]